Yervoy Survival Data From First-Line Study Sealed The Deal For FDA Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA approved Bristol-Myer’s Squibb’s metastatic melanoma immunotherapy Yervoy (ipilimumab) only after looking outside the BLA for assurance that the biologic’s effect was robust and validated.